Abstract
Despite significant improvements in early detection and refinements of therapeutic protocols over the last several decades, cancer remains one of the leading causes of death in North America. In particular, treatment of metastatic cancers is a highly desirable and yet still elusive goal of the oncologist. One strategy which holds promise is the use of self replicating viral strains with the ability to specifically kill tumour but not normal cells. These so-called “oncolytic viruses” are in general, attenuated for growth in normal cells but are able to exploit tumour specific, genetic defects to gain a growth advantage. In this review, we will discuss the virus:host cell interactions which help form the niche occupied by oncolytic viruses. The current and potential clinical applications / limitations will be discussed for oncolytic viruses from the herpesvirus, adenoviruses, picornavirus, rhabdovirus, and paramyxovirus families.
Keywords: Oncolytic Viruses, Tumour Hunters, Paramyxoviruses, Fibre Knob
Current Gene Therapy
Title: Oncolytic Viruses: Programmable Tumour Hunters
Volume: 2 Issue: 2
Author(s): J. C. Bell, K. A. Garson, B. D. Lichty and F. D. Stojdl
Affiliation:
Keywords: Oncolytic Viruses, Tumour Hunters, Paramyxoviruses, Fibre Knob
Abstract: Despite significant improvements in early detection and refinements of therapeutic protocols over the last several decades, cancer remains one of the leading causes of death in North America. In particular, treatment of metastatic cancers is a highly desirable and yet still elusive goal of the oncologist. One strategy which holds promise is the use of self replicating viral strains with the ability to specifically kill tumour but not normal cells. These so-called “oncolytic viruses” are in general, attenuated for growth in normal cells but are able to exploit tumour specific, genetic defects to gain a growth advantage. In this review, we will discuss the virus:host cell interactions which help form the niche occupied by oncolytic viruses. The current and potential clinical applications / limitations will be discussed for oncolytic viruses from the herpesvirus, adenoviruses, picornavirus, rhabdovirus, and paramyxovirus families.
Export Options
About this article
Cite this article as:
Bell C. J., Garson A. K., Lichty D. B. and Stojdl D. F., Oncolytic Viruses: Programmable Tumour Hunters, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605582
DOI https://dx.doi.org/10.2174/1566523024605582 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Synthesis, Characterization, and Molecular Structure of a Novel Zinc (II) Complex: Assessment of Impact of MDR1Pgp Expression on its Cytotoxic Activity
Medicinal Chemistry Current and Potential Use of Citrus Essential Oils
Current Organic Chemistry Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry Collagen: The Oldest Scaffold for Tissue Regeneration
Current Tissue Engineering (Discontinued) Recent Advances in the Characterization of Genetic Factors Involved in Human Susceptibility to Infection by Schistosomiasis
Current Genomics A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses